Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

• This invention relates to bifunctional antibodies and to their use in targeting anti-tumour agents in vivo .
• the targeting of therapeutic agents to particular sites in vivo is well known.
• it is very desirable to target anti-cancer agents to a tumour site to increase the concentration of the agent at the site and thereby improve its effectiveness in neutralising the tumour.
• agents that target tumours are well known, many of these relying on the specificity of monoclonal antibodies for delivering the diagnostic or therapeutic agent to the target site.
• One approach has been to use a radionuclide-antibody conjugate which localises at a target tissue where the radionuclide may exert its cytotoxic effect.
• US-A-5630996 describes one approach that uses antibody-streptavidin conjugates to target a radionuclide- labelled biotin.
• Streptavidin has high affinity for biotin and is able to localise the radionuclide at the target site through the biotin-streptavidin interaction.
• streptavidin is a protein that is immunogenic in humans and consequently may not be suitable for repeated long-term therapeutic use.
• US-A-5591828 discloses bispecific antibodies that have affinity for metal chelates and for a particular protein epitope.
• the chelates, EDTA-Y 90 and DTPA-Y 90 preferably require the covalent addition of a fos-peptide which interacts with a jun-peptide on the antibody, to localise sufficient Y 90 to the target site.
• dissociation may occur between the chelating agent (EDTA) and the radionuclide (Y 90 ). Therefore, localisation at the tumour site may not be efficient, and the process of producing the fos-peptide-metal chelate conjugate is lengthy and unsuitable for large-scale manufacture.
• the present invention relates to bifunctional antibodies which have affinity for both an antigen present at a tumour site, and for a therapeutic or diagnostic agent, wherein the agent is an organic molecule that is radiolabelled or is covalently bound to a cytotoxic agent.
• the organic molecule is bound to an enzyme capable of converting a prodrug into a cytotoxic form.
• the invention therefore provides a means for increasing the localisation of a therapeutic agent at a target site in a mammal, by the sequential administration of the bifunctional antibody and the organic molecule.
• the invention may have use in therapeutic or diagnostic applications.
• the organic molecule is biotin or an organic molecule which exhibits good penetration at a target site and otherwise neutral biodistribution in vivo .
• One of the advantages of the present invention is that it is possible to administer a cytotoxic agent which will localise at the desired target due to the interaction with antibody, but which will have reduced toxicity to non-target tissues, as unbound agent will be cleared efficiently from the body.
• the cytotoxic agent is a radionuclide, and is covalently linked to the organic molecule, or is itself part of the organic molecule.
• the radionuclide may be chosen to provide a therapeutic effect, e.g. as an anti-tumour agent, or may be administered for diagnostic purposes, e.g. tumour imaging.
• the organic molecule is linked to an enzyme that can be used to convert a suitable prodrug into an active cytotoxic form.
• the antibodies of the present invention may be produced using conventional techniques, for example, hybridoma synthesis, recombinant DNA techniques or phage display.
• the antibodies may be derived from any species, including rodent, although it is preferred that the antibodies are derived from mammals other than rodents, e.g. sheep, goats or cows, to generate high-affinity antibodies .
• the antibodies will have an affinity of at least 10 10 1/mol, preferably 10 11 1/mol, more preferably 10 12 1/mol and most preferably 10 13 1/mol for the respective ligands.
• a bifunctional antibody according to the invention may be whole antibody or may be a fragment thereof, e.g. f (ab) 2 .
• the antibody may comprise two single chain fv fragments.
• the preparation of bifunctional sFvs is well known. For example, Carter et al . r Current Opinion in Biotechnology 1997, 8: 449-454, discloses the production of bifunctional sFvs using phage display libraries.
• the antibodies may be modified by recombinant DNA techniques to "humanise" the antibodies, making them less immunogenic when administered to a patient.
• the humanised antibody should comprise at least the hypervariable region from both a monoclonal antibody having affinity for target antigen, and a monoclonal antibody having affinity for the organic molecule.
• the remainder of the antibody variable region may be of human immunoglobulin.
• a higher proportion of human immunoglobulin may be present in a whole antibody or a fragment, e.g. F(ab') 2 .
• the fragment may comprise hypervariable regions as described above and, optionally, the variable framework from human immunoglobulin.
• the antibody will have affinity for a particular target site.
• the target site will be a tumour and the antibody will have affinity for a tumour-associated antigen.
• a tumour-associated antigen is the carcinoembryonic antigen (CEA) which is found on colorectal tumours and other adeno-carcinomas .
• CEA carcinoembryonic antigen
• the antibody has ligand- affinity for an organic molecule that is radiolabelled.
• the invention encompasses both the separate covalent attachment of a radionuclide to an organic molecule, and additionally the simple radiolabelling of a suitable atom on the organic molecule itself.
• the organic molecule may comprise a phosphorous or iodine atom which is radiolabelled to provide a cytotoxic organic molecule.
• Administration of the molecule will localise the radionuclide at a tumour site through binding to the antibody to exert a cytotoxic effect on the tumour. Radionuclides having a cytotoxic effect are well known.
• a preferred radionuclide that may be used in the invention is a radioisotope of iodine, e.g. I 123 , I 124 and I 125 which may be used for diagnostic purposes and I 131 which may be used in therapeutics .
• a further preferred radionuclide that may be used in the invention, is P 32 .
• the cytotoxic agent may also be a cytotoxic drug, e.g. ricin or calicheamycin.
• the organic molecule is linked (conjugated) to an enzyme.
• the enzyme is capable of converting a suitable prodrug into an active cytotoxic form.
• prodrug is used herein to define an inactive form of a drug which may be cleaved by enzymic action to release the therapeutically-active form.
• Suitable enzyme-prodrug systems are known to those skilled in the art and include carboxypeptidases and modified mustard gas derivatives .
• the organic molecules that are useful in the present invention must be capable of specific interaction with an antibody.
• the molecules must therefore be of a sufficient size to elicit an immune response for the production of the antibodies when conjugated to a protein carrier, or be of a sufficient size to facilitate antibody creation from antibody libraries, e.g. displayed on filamentous phage.
• the organic molecules linked to the cytotoxic agent or enzyme are capable of passing through the lining of the vasculature to reach the target site.
• the molecular weight of the organic molecules is preferably less than 1500, more preferably less than 1000.
• the organic molecules are preferably non-toxic when not radiolabelled.
• the labelled organic molecules should have a neutral biodistribution when administered to a patient in the absence of bispecific antibody, and it is preferable if molecules are chosen which do not accumulate in the thyroid and are rapidly cleared through the kidney. It is also beneficial if the molecules are easily derived from a non- labelled parent molecule and that the derived, labelled molecule is stable following administration.
• the conjugate should preferably be water-soluble, to facilitate preparation in suitable excipients.
• Suitable organic molecules include non-toxic compounds, although the molecules may be made cytotoxic by radiolabelling.
• the radio-labelled organic molecule is radio-labelled biotin.
• the molecule is of formula I
• the molecule is of formula II
• R 1 and R 2 are each, independently, a radiolabelled moiety, e.g. radiolabelled iodine, a methyl group or a phenyl group, and X 1 and X 2 are each, independently, a H or OH.
• Preferred radiolabelled molecules are N-(4-hydroxy- 3 , 5-diiodobenzoyl ) -1 , 6-hexanediamine and N- ( 2-hydroxy-3 , 5- diiodobenzoyl)-l, 6-hexanediamine, where either or each of the iodine atoms may be any of the radioisotopes I 123 , I 125 , I 124 and I 131 .
• the bispecific antibody and the cytotoxic agent may be formulated in a kit, e.g. comprising the two components separately packaged or in separate containers.
• Each component may be formulated with a suitable carrier or excipient, examples of which are well known, depending on the route of administration, e.g. oral or intravenous.
• the two components will usually be administered sequentially.
• the effective amount of each may readily be determined by the skilled person, and will depend on typical factors such as the location, severity and spread of the tumour, the condition of the subject etc. It is of course a feature of this invention that the amount of cytotoxic agent that is required will be less than in the absence of the antibody.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Veterinary Medicine (AREA)
• Genetics & Genomics (AREA)
• Animal Behavior & Ethology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Cell Biology (AREA)
• Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Epidemiology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=10838416

Family Applications (1)

Country Status (20)

Families Citing this family (3)

Family Cites Families (6)

• 1998
  • 1998-09-04 GB GBGB9819411.1A patent/GB9819411D0/en not_active Ceased
• 1999
  • 1999-09-06 MX MXPA01002349A patent/MXPA01002349A/es not_active Application Discontinuation
  • 1999-09-06 PL PL99346861A patent/PL346861A1/xx not_active Application Discontinuation
  • 1999-09-06 EP EP99943138A patent/EP1107995A2/de not_active Withdrawn
  • 1999-09-06 TR TR2001/03405T patent/TR200103405T2/xx unknown
  • 1999-09-06 CA CA002341753A patent/CA2341753A1/en not_active Abandoned
  • 1999-09-06 EA EA200100311A patent/EA200100311A1/ru unknown
  • 1999-09-06 ID IDW20010752A patent/ID28873A/id unknown
  • 1999-09-06 JP JP2000568876A patent/JP2002524470A/ja active Pending
  • 1999-09-06 AU AU56412/99A patent/AU5641299A/en not_active Abandoned
  • 1999-09-06 HU HU0104091A patent/HUP0104091A2/hu unknown
  • 1999-09-06 WO PCT/GB1999/002938 patent/WO2000014119A2/en not_active Application Discontinuation
  • 1999-09-06 IL IL14152499A patent/IL141524A0/xx unknown
  • 1999-09-06 TR TR2001/00651T patent/TR200100651T2/xx unknown
  • 1999-09-06 BR BR9913429-2A patent/BR9913429A/pt not_active IP Right Cessation
  • 1999-09-06 KR KR1020017002437A patent/KR20010072988A/ko not_active Application Discontinuation
  • 1999-09-06 CN CN99810368A patent/CN1315967A/zh active Pending
• 2001
  • 2001-02-26 ZA ZA200101574A patent/ZA200101574B/en unknown
  • 2001-02-26 BG BG105293A patent/BG105293A/bg unknown
  • 2001-03-02 NO NO20011102A patent/NO20011102L/no unknown
  • 2001-03-02 HR HR20010154A patent/HRP20010154A2/hr not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events